Global Glutathione Market Strategic Research Report 2026-2031

Publication ID:

NAV0926008

Publication Date:

September 18, 2026

Pages:

212

Countries:

Global [1]

The global glutathione market is estimated at approximately USD 301.3 million in 2025, growing at a 7.83% CAGR to approximately USD 473.6 million by 2031. This figure reflects a rigorous triangulation methodology: independently published market research estimates were screened for scope consistency and cross-validated for convergence, since different publishers define this market differently -- our base-year anchor is our own synthesis of the estimates found to share a consistent, comparable scope, not a figure adopted directly from any single source.

Real, Current Competitive Intelligence

Kyowa Hakko Bio's amino acid and HMO business -- which historically included bulk glutathione-adjacent fermentation manufacturing -- was divested to a Chinese fermentation-technology acquirer for approximately JPY 10.5 billion (~$68 million), completed July 1, 2025. Setria® Glutathione itself was retained by Kyowa Hakko Bio as a branded specialty product, reflecting a deliberate strategic refocus toward higher-margin specialty ingredients. Separately, KOHJIN Life Sciences' current parent company is confirmed across multiple independent, current sources, ensuring this report reflects today's verified corporate structure.

Scope of the Global Glutathione Market Strategic Research Report

This report provides market sizing (value and volume) across type and application segments, and regional/country splits, through 2031, grounded in real, current competitive intelligence.

Segment by Type

Reduced Glutathione (GSH)
Oxidized Glutathione (GSSG)

Segment by Application

Pharmaceuticals & API
Nutraceuticals / Health Products
Cosmetics & Personal Care
Food & Beverage
Other (Reagent, Diagnostic)

Who Can Use This Report?

This research report is ideal for people who need a granular, evidence-based view of the global glutathione market grounded in real, current competitive developments. Some of the intended users are:

Procurement and sourcing teams evaluating supplier stability following recent ownership and portfolio changes among key manufacturers
Corporate strategy and M&A teams assessing competitive positioning in specialty fermentation ingredients
Nutraceutical and cosmetic formulators tracking branded-ingredient supply relationships
Investment analysts requiring current, verified competitive-landscape detail

Executive Summary
1. 1.1 Market Synopsis
2. 1.2 Structural Market Context
3. 1.3 Key Findings
4. 1.4 Methodology Transparency and Competitive-Intelligence Differen…
5. 1.5 Forecast Summary and Investment Relevance
Industry Overview & Forecast
1. 2.1 Market Definition & Scope
2. 2.2 Market Value & Volume Forecast, 2026–2031
3. 2.2.1 Headline Market Sizing
4. 2.2.2 Value Forecast Summary Table
5. 2.3 Volume Analysis
6. 2.3.1 Year-by-Year Volume Progression
7. 2.3.2 Volume Trend and Demand Drivers
8. 2.4 Third-Party Estimate Reconciliation
9. 2.5 Historical Market Review, 2022–2025
10. 2.6 Scenario Analysis: Base, Bull, and Bear Cases
11. 2.6.1 Base Case
12. 2.6.2 Bull Case
13. 2.6.3 Bear Case
Market Segmentation by Type
1. 3.1 Market by Type Overview
2. 3.2 Reduced Glutathione (GSH)
3. 3.2.1 Value Analysis
4. 3.2.2 Volume Analysis
5. 3.3 Oxidized Glutathione (GSSG)
6. 3.3.1 Value Analysis
7. 3.3.2 Volume Analysis
8. 3.4 Comparative Type Analysis
Market Segmentation by Application
1. 4.1 Market by Application Overview
2. 4.2 Pharmaceuticals & API
3. 4.2.1 Segment Scale and Forecast Trajectory
4. 4.2.2 Demand Drivers and Therapeutic Applications
5. 4.2.3 Grade Requirements and Supplier Implications
6. 4.2.4 Volumetric Outlook
7. 4.3 Nutraceuticals / Health Products
8. 4.3.1 Segment Scale and Forecast Trajectory
9. 4.3.2 Demand Drivers
10. 4.3.3 Branded Specialty Dynamics: The Setria® and OPITAC™ Context
11. 4.3.4 Volume and Pricing Dynamics
12. 4.4 Cosmetics & Personal Care
13. 4.4.1 Segment Scale and Forecast Trajectory
14. 4.4.2 Demand Drivers and Application Context
15. 4.4.3 Regulatory Risk and Restraints
16. 4.4.4 Competitive and Sourcing Implications
17. 4.5 Food & Beverage
18. 4.5.1 Segment Scale and Forecast Trajectory
19. 4.5.2 Application Detail
20. 4.5.3 Growth Constraints
21. 4.6 Other: Reagent and Diagnostic
22. 4.6.1 Segment Scale and Forecast Trajectory
23. 4.6.2 Reagent and Research-Grade Demand
24. 4.6.3 Diagnostic and Bioprocessing Growth Drivers
25. 4.6.4 Strategic Note on Segment Sizing
26. 4.7 Cross-Segment Synthesis and Strategic Implications
Regional Market Forecast
1. 5.1 Asia Pacific
2. 5.1.1 Regional Overview
3. 5.1.2 Key Growth Drivers
4. 5.1.3 Regulatory & Infrastructure Landscape
5. 5.1.4 Country-Level Analysis
6. 5.1.4.1 China
7. 5.1.4.2 Japan
8. 5.1.4.3 India
9. 5.1.4.4 South Korea
10. 5.1.4.5 Rest of Asia Pacific
11. 5.1.5 Market Forecast 2025–2031
12. 5.2 Europe
13. 5.2.1 Regional Overview
14. 5.2.2 Key Growth Drivers
15. 5.2.3 Regulatory & Infrastructure Landscape
16. 5.2.4 Country-Level Analysis
17. 5.2.5 Market Forecast 2025–2031
18. 5.3 North America
19. 5.3.1 Regional Overview
20. 5.3.2 Key Growth Drivers
21. 5.3.3 Regulatory & Infrastructure Landscape
22. 5.3.4 Country-Level Analysis
23. 5.3.5 Market Forecast 2025–2031
24. 5.4 Latin America
25. 5.4.1 Regional Overview
26. 5.4.2 Key Growth Drivers
27. 5.4.3 Regulatory & Infrastructure Landscape
28. 5.4.4 Country-Level Analysis
29. 5.4.5 Market Forecast 2025–2031
30. 5.5 Middle East & Africa
31. 5.5.1 Regional Overview
32. 5.5.2 Key Growth Drivers
33. 5.5.3 Regulatory & Infrastructure Landscape
34. 5.5.4 Country-Level Analysis
35. 5.5.5 Market Forecast 2025–2031
Country-Level Market Forecast
1. 6.1 Asia Pacific
2. 6.1.1 China
3. 6.1.2 Japan
4. 6.1.3 India
5. 6.1.4 South Korea
6. 6.1.5 Rest of Asia-Pacific
7. 6.2 Europe
8. 6.2.1 Germany
9. 6.2.2 United Kingdom
10. 6.2.3 France
11. 6.2.4 Rest of Europe
12. 6.3 North America
13. 6.3.1 USA
14. 6.3.2 Rest of North America
15. 6.4 Latin America
16. 6.4.1 Brazil
17. 6.4.2 Rest of Latin America
18. 6.5 Middle East & Africa
19. 6.5.1 Saudi Arabia
20. 6.5.2 Rest of Middle East & Africa
Growth Drivers & Inhibitors
1. 7.1 Market Dynamics Framework
2. 7.2 Nutraceutical and Healthy-Aging Demand Growth
3. 7.2.1 Structural Demand Trajectory
4. 7.2.2 Immune Health Positioning as a Demand Accelerant
5. 7.2.3 Branded Ingredient Infrastructure as a Demand Enabler
6. 7.3 Cosmetic and Skin-Brightening Demand
7. 7.3.1 Regional Concentration and Market Significance
8. 7.3.2 Regulatory Environment as a Dual-Edged Factor
9. 7.4 Branded Specialty Positioning Following Real 2025 Portfolio Re…
10. 7.4.1 The Strategic Significance of Kyowa Hakko Bio's 2025 Divestiture
11. 7.4.2 Implications for Competitive Positioning
12. 7.4.3 KOHJIN Life Sciences and the Role of Corporate Ownership Struc…
13. 7.5 Pharmaceutical Demand Foundations
14. 7.5.1 Established and Durable API Demand
15. 7.5.2 Emerging Biopharma and Diagnostic Demand
16. 7.6 Market Restraints: Data Opacity and Competitive Instability
17. 7.6.1 Structural Data Opacity as a Genuine Market Friction
18. 7.6.2 Competitive Instability Risk Following Real Ownership Changes
19. 7.6.3 Fragmented Chinese Competitive Base and Price Discovery Challe…
20. 7.7 Opportunities and White-Space Analysis
21. 7.7.1 Premiumization as the Primary Value-Creation Vector
22. 7.7.2 Competitive Consolidation as a Structural Opportunity
23. 7.7.3 Diagnostic and High-Purity Reagent Market Development
24. 7.8 Summary Assessment of Dynamic Balance
Key Company Profiles
1. 8.1 Kyowa Hakko Bio Co., Ltd.
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 KOHJIN Life Sciences Co., Ltd.
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 Shandong Jincheng Pharmaceutical Group
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2025–2031)
22. 8.4 Merck KGaA
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. 8.4.5 SWOT Analysis
28. 8.4.6 Strategic Implications (2025–2031)
29. 8.5 Kaneka Corporation
30. 8.5.1 Company Overview
31. 8.5.2 Key Products & Segments
32. 8.5.3 Financial Performance (2023–2025)
33. 8.5.4 Business Strategy
34. 8.5.5 SWOT Analysis
35. 8.5.6 Strategic Implications (2025–2031)
36. 8.6 Gnosis by Lesaffre
37. 8.6.1 Company Overview
38. 8.6.2 Key Products & Segments
39. 8.6.3 Financial Performance (2023–2025)
40. 8.6.4 Business Strategy
41. 8.6.5 SWOT Analysis
42. 8.6.6 Strategic Implications (2025–2031)
Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.1.1 Estimated Market Share: Top 5 Players, 2025
3. 9.1.2 Competitive Intensity: Moderate-to-High
4. 9.2 Competitive Intensity Assessment
5. 9.2.1 Tier Classification and Revenue Context
6. 9.2.2 Capacity vs. Demand Dynamics
7. 9.2.3 Pricing Environment
8. 9.2.4 Barriers to Entry and Exit
9. 9.3 Key Player Strategies & Positioning
10. 9.4 Competitive Dynamics & Strategic Outlook
11. 9.4.1 Emerging Competitive Threats
12. 9.4.2 Consolidation vs. Fragmentation Outlook
13. 9.4.3 Competitive Response Matrix
14. 9.4.4 Strategic Recommendations for 2025–2031
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Political Factors
2. 11.1.1 Regulatory Posture Toward Nutraceutical and Cosmetic Active In…
3. 11.1.2 Geopolitical Dynamics and Supply Chain Politics
4. 11.1.3 Trade Policy and Tariff Exposure
5. 11.2 Economic Factors
6. 11.2.1 Global Market Size and Growth Trajectory
7. 11.2.2 Consumer Spending Patterns and Premiumisation
8. 11.2.3 Raw Material and Energy Cost Dynamics
9. 11.2.4 Currency Dynamics and Export Economics
10. 11.2.5 Healthcare Expenditure and Pharmaceutical Demand
11. 11.3 Social and Demographic Factors
12. 11.3.1 Ageing Demographics and Antioxidant Demand
13. 11.3.2 The Wellness Economy and Self-Directed Health Management
14. 11.3.3 Beauty Standards and Skin-Brightening Cultural Dynamics
15. 11.3.4 Dietary and Lifestyle Influences
16. 11.4 Technological Factors
17. 11.4.1 Fermentation Technology and Production Efficiency
18. 11.4.2 Bioavailability Innovation and Delivery Technology
19. 11.4.3 Analytical and Quality Assurance Technology
20. 11.4.4 Digital Health and Personalised Nutrition Technology
21. 11.5 Legal and Regulatory Factors
22. 11.5.1 Ingredient Classification and Permissibility
23. 11.5.2 Pharmaceutical Good Manufacturing Practice Compliance
24. 11.5.3 Cosmetic Regulatory Frameworks
25. 11.5.4 Intellectual Property and Brand Protection
26. 11.6 Environmental Factors
27. 11.6.1 Fermentation Sustainability and Resource Intensity
28. 11.6.2 Carbon Footprint and Climate Risk
29. 11.6.3 Packaging and Circular Economy Pressures
30. 11.6.4 Biodiversity and Biosafety of Fermentation Organisms
SWOT Analysis
1. 12.1 Introduction
2. 12.2 Market-Level Strengths
3. 12.2.1 Scientifically Validated Biological Relevance
4. 12.2.2 Diversified Multi-Sector Application Base
5. 12.2.3 Established, High-Barrier Fermentation Production Technology
6. 12.2.4 Branded Ingredient Infrastructure and Traceability Premium
7. 12.2.5 Favorable Demographic and Epidemiological Tailwinds
8. 12.3 Market-Level Weaknesses
9. 12.3.1 Bioavailability Controversy and Oral Delivery Limitations
10. 12.3.2 Absence of Segment-Level Financial Transparency
11. 12.3.3 Supply Chain Geographic Concentration Risk
12. 12.3.4 Premium Pricing Vulnerability in Commodity-Grade Segments
13. 12.4 Strategic Opportunities
14. 12.4.1 Liposomal and Next-Generation Delivery Technology Adoption
15. 12.4.2 Asian Skin-Brightening and Cosmeceutical Market Expansion
16. 12.4.3 Functional Food and Beverage Channel Development
17. 12.4.4 Strategic M&A and Industry Consolidation
18. 12.4.5 Pharmaceutical Pipeline Expansion and Clinical Indication Deve…
19. 12.5 External Threats
20. 12.5.1 Regulatory Tightening on Health Claims and Cosmeceutical Labeling
21. 12.5.2 Ingredient Competition from Substitute Antioxidants and Precur…
22. 12.5.3 Geopolitical and Trade Friction Risk
23. 12.5.4 Consumer Credibility Risk from Market Adulteration and Label F…
24. 12.5.5 Macroeconomic Sensitivity in Discretionary Supplement Channels
25. 12.6 Integrated SWOT Assessment
Future Trends & Outlook
1. 13.1 Continued Premiumization and Branded Specialty Positioning
2. 13.2 Competitive Consolidation Following Real 2025 Ownership Changes
3. 13.3 Long-Term Market Outlook (2032–2035)
4. 13.4 Investment & M&A Activity Outlook

List of Exhibits

2.1 Exhibit 2.1: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
2.2 Exhibit 2.2: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
2.3 Exhibit 2.3: Forecast of Global (in USD Mn)
2.4 Exhibit 2.4: Forecast of Asia Pacific (in USD Mn)
2.5 Exhibit 2.5: Forecast of Europe (in USD Mn)
2.6 Exhibit 2.6: Forecast of North America (in USD Mn)
2.7 Exhibit 2.7: Forecast of Latin America (in USD Mn)
2.8 Exhibit 2.8: Forecast of Middle East & Africa (in USD Mn)
2.9 Exhibit 2.9: Forecast of Global (in mt)
2.10 Exhibit 2.10: Forecast of Asia Pacific (in mt)
2.11 Exhibit 2.11: Forecast of Europe (in mt)
2.12 Exhibit 2.12: Forecast of North America (in mt)
2.13 Exhibit 2.13: Forecast of Latin America (in mt)
2.14 Exhibit 2.14: Forecast of Middle East & Africa (in mt) 2.14
3.15 Exhibit 3.15: Forecast of Reduced Glutathione (GSH) (in USD Mn)
3.16 Exhibit 3.16: Forecast of Reduced Glutathione (GSH) (in mt)
3.17 Exhibit 3.17: Forecast of Oxidized Glutathione (GSSG) (in USD Mn)
3.18 Exhibit 3.18: Forecast of Oxidized Glutathione (GSSG) (in mt)
4.19 Exhibit 4.19: Forecast of Pharmaceuticals & API (in USD Mn)
4.20 Exhibit 4.20: Forecast of Pharmaceuticals & API (in mt)
4.21 Exhibit 4.21: Forecast of Nutraceuticals / Health Products (in USD Mn)
4.22 Exhibit 4.22: Forecast of Nutraceuticals / Health Products (in mt)
4.23 Exhibit 4.23: Forecast of Cosmetics & Personal Care (in USD Mn)
4.24 Exhibit 4.24: Forecast of Cosmetics & Personal Care (in mt)
4.25 Exhibit 4.25: Forecast of Food & Beverage (in USD Mn)
4.26 Exhibit 4.26: Forecast of Food & Beverage (in mt)
4.27 Exhibit 4.27: Forecast of Other (Reagent, Diagnostic) (in USD Mn)
4.28 Exhibit 4.28: Forecast of Other (Reagent, Diagnostic) (in mt)
6.29 Exhibit 6.29: Forecast of Asia Pacific (in USD Mn)
6.30 Exhibit 6.30: Forecast of China (in USD Mn)
6.31 Exhibit 6.31: Forecast of Japan (in USD Mn)
6.32 Exhibit 6.32: Forecast of India (in USD Mn)
6.33 Exhibit 6.33: Forecast of South Korea (in USD Mn)
6.34 Exhibit 6.34: Forecast of Rest of Asia-Pacific (in USD Mn)
6.35 Exhibit 6.35: Forecast of Asia Pacific (in mt)
6.36 Exhibit 6.36: Forecast of China (in mt)
6.37 Exhibit 6.37: Forecast of Japan (in mt)
6.38 Exhibit 6.38: Forecast of India (in mt)
6.39 Exhibit 6.39: Forecast of South Korea (in mt)
6.40 Exhibit 6.40: Forecast of Rest of Asia-Pacific (in mt)
6.41 Exhibit 6.41: Forecast of Europe (in USD Mn)
6.42 Exhibit 6.42: Forecast of Germany (in USD Mn)
6.43 Exhibit 6.43: Forecast of United Kingdom (in USD Mn)
6.44 Exhibit 6.44: Forecast of France (in USD Mn)
6.45 Exhibit 6.45: Forecast of Rest of Europe (in USD Mn)
6.46 Exhibit 6.46: Forecast of Europe (in mt)
6.47 Exhibit 6.47: Forecast of Germany (in mt)
6.48 Exhibit 6.48: Forecast of United Kingdom (in mt)
6.49 Exhibit 6.49: Forecast of France (in mt)
6.50 Exhibit 6.50: Forecast of Rest of Europe (in mt)
6.51 Exhibit 6.51: Forecast of North America (in USD Mn)
6.52 Exhibit 6.52: Forecast of USA (in USD Mn)
6.53 Exhibit 6.53: Forecast of Rest of North America (in USD Mn)
6.54 Exhibit 6.54: Forecast of North America (in mt)
6.55 Exhibit 6.55: Forecast of USA (in mt)
6.56 Exhibit 6.56: Forecast of Rest of North America (in mt)
6.57 Exhibit 6.57: Forecast of Latin America (in USD Mn)
6.58 Exhibit 6.58: Forecast of Rest of Latin America (in USD Mn)
6.59 Exhibit 6.59: Forecast of Latin America (in mt)
6.60 Exhibit 6.60: Forecast of Rest of Latin America (in mt)
6.61 Exhibit 6.61: Forecast of Middle East & Africa (in USD Mn)
6.62 Exhibit 6.62: Forecast of Middle East & Africa (in USD Mn)
6.63 Exhibit 6.63: Forecast of Middle East & Africa (in mt)
6.64 Exhibit 6.64: Forecast of Middle East & Africa (in mt)

Kyowa Hakko Bio Co. Ltd., KOHJIN Life Sciences Co. Ltd., Shandong Jincheng Pharmaceutical Group, Merck KGaA, Kaneka Corporation, Gnosis by Lesaffre

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.